Short Interest in Avalon GloboCare Corp. (NASDAQ:ALBT) Increases By 31.1%

Posted by on May 1st, 2026

Avalon GloboCare Corp. (NASDAQ:ALBT – Get Free Report) was the target of a significant growth in short interest in the month of April. As of April 15th, there was short interest totaling 926,778 shares, a growth of 31.1% from the March 31st total of 706,973 shares. Approximately 11.7% of the company’s shares are sold short. Based on an average daily trading volume, of 2,914,701 shares, the short-interest ratio is presently 0.3 days.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Avalon GloboCare in a research note on Monday, April 20th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

Check Out Our Latest Report on Avalon GloboCare

Avalon GloboCare Price Performance

ALBT stock traded down $0.01 on Friday, hitting $0.40. 59,328 shares of the company were exchanged, compared to its average volume of 5,510,436. Avalon GloboCare has a twelve month low of $0.34 and a twelve month high of $4.74. The business’s fifty day moving average is $0.61 and its two-hundred day moving average is $1.12. The stock has a market capitalization of $3.30 million, a price-to-earnings ratio of -0.11 and a beta of 0.10.

Avalon GloboCare (NASDAQ:ALBT – Get Free Report) last issued its quarterly earnings results on Monday, March 30th. The company reported $0.46 EPS for the quarter.

Avalon GloboCare Company Profile

(Get Free Report)

Avalon GloboCare is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection.

Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies.

Featured Stories

Receive News & Ratings for Avalon GloboCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalon GloboCare and related companies with MarketBeat.com's FREE daily email newsletter.